, Tracking Stock Market Picks
Enter Symbol:
Nektar Therapeutics (NKTR) [hlAlert]

up 115.73 %

Nektar Therapeutics (NKTR) rated Outperform by William Blair

Posted on: Tuesday,  Apr 7, 2009  8:25 AM ET by William Blair

William Blair rated Outperform Nektar Therapeutics (NASDAQ: NKTR) on 04/07/2009, when the stock price was $5.02. Since
then, Nektar Therapeutics has gained 115.74% as of 12/07/2015's recent price of $10.83.
If you would have followed this William Blair's recommendation on NKTR, you would have gained 115.73% of your investment in 2435 days.

Nektar Therapeutics is a biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to improve the benefits of drugs for patients. The Company?s product pipeline is comprised of drug candidates across a number of therapeutic areas including oncology, pain, anti-infectives, anti-viral and immunology. Nektar?s research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. It creates its drug candidates by using its chemistry platform to modify the chemical structure of drugs using polymer conjugates. Nektar?s drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient.

The Equity Research department provides the firm's clients with in-depth investment analysis and investment recommendations. Acting as the company's laboratory for new investment ideas, it specializes in providing investment analysis on quality growth companies. Located together in our Chicago office, our equity analysts currently follow a universe of nearly 360 companies.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
4/7/2009 8:25 AM Buy
as of 12/31/2009
1 Week up  22.73 %
1 Month up  27.66 %
3 Months up  14.16 %
1 YTD up  121.51 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy